Skip to content

Author

L. Heinzerling

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Immune-Related Adverse Events: Findings From a Population-Based Study.

Immune checkpoint inhibitors (ICIs) are effective for several tumor entities but cause immune-related adverse events (irAEs). These side effects may affect any organ and often lead to ICI discontinuation, hospitalization, long-term complications, or sequelae. To assess the burden of irAEs, this longitudinal observation...

L. Heinzerling, I. Seemann, A. Ingram et al. · 0 citations
Open access Oct 2026

Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

Neoadjuvant immune checkpoint inhibitors (ICIs) are standard of care for resectable stage IIIB-D melanoma, but knowledge gaps remain regarding optimal treatment type, long-term survival, postsurgical management and clinical, histopathological or molecular subgroups. We analyzed 1,038 patients treated with neoadjuvant I...

Georgina V. Long, I. Pires da Silva, Kristen A. Perry et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.